Related posts

Markets recover, oil sinksTSX climbs, Wall Street mixedTrump tariffs sink markets
Investor Insights

This summary was created by AI, based on 11 opinions in the last 12 months.

Moderna (MRNA-Q) is currently facing significant challenges, leading to negative sentiment among experts. The company's pipeline post-Covid is promising but high-risk, with ongoing investments in R&D exceeding their revenues of $3 billion, resulting in substantial losses. Experts highlight concerns over unmet expectations in vaccine development, particularly regarding personalized cancer vaccines and the application of AI technologies. Despite recent price rallies following favorable news related to new vaccine developments, the general outlook remains pessimistic, with predictions of continued financial losses. Many experts suggest that Moderna's current valuation is high given the uncertainty surrounding its ability to deliver on its ambitious promises.

Consensus
Negative
Valuation
Overvalued
Similar
Pfi127
DON'T BUY

No revenue growth and the company seems unconcerned that they are losing so much money. This is why sentiment has turned against MRNA.

DON'T BUY

Post-Covid, they have a pipeline of drugs under development, related to vaccines and cancer. This is higher-risk in health care. They have $3 billion in revenues, but are spending a lot in R&D, more than their revenues, so they're not profitable. 

DON'T BUY

They aren't delivering on the things--vaccine results--they promise. He struggles with this stock.

DON'T BUY

They should have done something with the money they had, and are now losing money hand over fist.

DON'T BUY

Down 33% the past month and could fall more. It isn't making any money and isn't delivering cancer vaccines.

DON'T BUY

They aren't producing the personalized cancer vaccines he expected, nor using AI as he hoped.

DON'T BUY

Moderna rallied 29% in May after a good report and news on developing a bird flu vaccine to fight that epidemic. Another boost came when the government approved their RSV vaccine. But Moderna is expected to lose money in the foreseeable future. Instead, look at biopharma.

DON'T BUY

It's had a huge price surge recently and is now too pricey. Prefers Pfizer.

WATCH

A staple, and that sector is starting to outperform the market. A value play. His target is around $200-ish, if it can break resistance around $140. If it fails, give it a few days, and then walk away if you have to.

WAIT

They have special technology; this morning they announced a collaboration with AI. Shares have been declining and there are sellers everywhere. You have to wait until they invent the special vaccines en masse they promised.

BUY ON WEAKNESS

Believes in the CEO and their technology. Buy below $100.

DON'T BUY

Down 44% in 2023. They made the first Covid vaccine and made a ton of sales, but they suffer losses now. It didn't pull off a cancer vaccine as some hoped for. But it's up 9% in the past week. Maybe there's hope.

DON'T BUY

Covid vaccine was its first commercial product, and it did well. That's trailing off. Investing in drug pipeline, and it's hard to determine when products might be approved and launched. Her preference is a more established company with a pipeline.

RISKY
JNJ question

A good mix of consumer goods and healthcare, but the PE is extended. Prefers to buy Pfizer for its growth and lower PE. He might even roll the dice with Moderna. Or buy the IBB, biotech ETF.

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick May 04/23, Down 19.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with MRNA has triggered its stop at $110.  To remain disciplined we recommend covering the position at this time.  

Showing 1 to 15 of 61 entries

Moderna(MRNA-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 8

Total Signals / Votes : 9

Stockchase rating for Moderna is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Moderna(MRNA-Q) Frequently Asked Questions

What is Moderna stock symbol?

Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q

Is Moderna a buy or a sell?

In the last year, 9 stock analysts published opinions about MRNA-Q. 1 analyst recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Moderna.

Is Moderna a good investment or a top pick?

Moderna was recommended as a Top Pick by on . Read the latest stock experts ratings for Moderna.

Why is Moderna stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Moderna worth watching?

9 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.

What is Moderna stock price?

On 2025-03-13, Moderna (MRNA-Q) stock closed at a price of $34.3.